Brief: Spero Therapeutics Announces Special Protocol Assessment With FDA For Phase 3 Pivot-Po Trial Of Tebipenem HBR
31/07/2023 13:18
July 31 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES SPECIAL PROTOCOL ASSESSMENT
AGREEMENT WITH FDA FOR PHASE 3 PIVOT-PO TRIAL OF TEBIPENEM HBR
* SPERO THERAPEUTICS INC - SPERO TO RECEIVE $30 MILLION
DEVELOPMENT MILESTONE PAYMENT FROM GSK
* SPERO THERAPEUTICS INC - PHASE 3 PIVOT-PO TRIAL IS
EXPECTED TO
BEGIN WITH FIRST PATIENT, FIRST VISIT IN 4Q 2023
Source text for Eikon: ID:nGNX9wX5DB
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)